SphingoTec GmbH (“SphingoTec”) announced today that the Acute Disease Quality Initiative (ADQI) recommends the use of novel biomarkers for AKI, including functional biomarkers as penKid®.
Scientific Publications
Browse our scientific publications to learn more about how our biomarkers can impact patient care.
Learn more
Downloads
Discover our brochures, product cataloge and white…
SphingoTec is collaborating with leading hospitals in Europe, the US, and Asia, a growing network of distribution partners, global IVD companies (out-licensing) and pharmaceutical companies…
On the basis of optimized protocols, we provide reliable services for competitive prices. Below you will find the full MTP biomarker assay range:
Get in touch with us
Do you have any questions…
The Uniklinik RWTH Aachen (“Uniklinik RWTH Aachen”) has successfully translated the collaboration for research and biomarker validation with SphingoTec GmbH (“SphingoTec”) into clinical routine.
Team
We know great work begins with great people. Our skilled international team has a breadth of experience in life sciences, biotechnology, and the clinical diagnostics and laboratory…
Critical care settings
SphingoTec identified major pathways driving mortality in critical care and has developed specific biomarkers predicting, diagnosing and monitoring these major mortality…
